$19.99
-0.66 (-3.20%)
Open$20.59
Previous Close$20.65
Day High$20.61
Day Low$19.51
52W High$38.72
52W Low$1.75
Volume—
Avg Volume12.1K
Market Cap35.43M
P/E Ratio—
EPS$-10.46
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-33.6% upside
Current
$19.99
$19.99
Target
$13.27
$13.27
$11.80
$13.27 avg
$20.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.74M | 18.13M | 17.61M |
| Net Income | 675.0K | 507.1K | 519.2K |
| Profit Margin | 3.4% | 2.8% | 3.0% |
| EBITDA | 1.03M | 911.5K | 901.4K |
| Free Cash Flow | 725.0K | 739.6K | 699.1K |
| Rev Growth | -5.2% | +2.0% | -8.0% |
| Debt/Equity | 1.19 | 0.81 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |